Santoso Anwar, Maulana Rido, Alzahra Fatimah, Maghfirah Irma, Putrinarita Agnes Dinar, Heriansyah Teuku
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Harapan Kita Hospital, National Cardiovascular CentreJakarta, Indonesia.
Faculty of Medicine, Muhammadiyah Jakarta UniversityJakarta, Indonesia.
Am J Cardiovasc Dis. 2017 Dec 20;7(6):122-133. eCollection 2017.
Previous studies suggested that some types of single nucleotide polymorphisms (SNPs) in PLA2G7 genes, encoding Lp-PLA2 have been reported to yield an antiatherogenic effect, but other studies mentioned otherwise. Thus, a comprehensive study to explore the effect of SNPs in PLA2G7 genes (V279F, A379V, R92H, I198T) toward clinical atherosclerosis is needed.
We searched eligible studies from PubMed, EBSCO, ProQuest, Science Direct, Springer, and Cochrane databases for case-control studies to assess the between four types of SNPs in PLA2G7 gene with risk of clinical atherosclerosis (CVD = cardiovascular disease, CAD = coronary artery disease, PAD = peripheral artery disease, ischemic stroke). All studies were assessed under Hardy-Weinberg Equilibrium, an additive model. This meta-analysis was performed by RevMan 5.3 to provide pooled estimate for odds ratio (ORs) with 95% confidence intervals (95% CIs).
Fourteen clinical studies met our inclusion criteria. Those included 12,432 patients with clinical atherosclerosis and 10,171 were controls. We found that ORs of two variants SNPs (V279F, R92H) were associated with clinical atherosclerosis {V279F, OR = 0.88 (95% CI, 0.81-0.95); p = 0.0007, I = 40%}, {R92H, OR = 1.29 (95% CI, 1.09-1.53); p = 0.003, I = 73%}. Meanwhile, there was no significant associations between the other two, A379V {OR = 1.08 (95% CI, 0.93-1.26); p = 0.31, I = 78%} and I198T {OR = 1.12 (95% CI = 0.79-1.59); p = 0.53, I = 81%}.
These results suggested that V279F polymorphism in PLA2G7 gene has a protective effect for clinical atherosclerosis, whereas R92H polymorphism might contribute toward increased risk of clinical atherosclerosis.
先前的研究表明，编码Lp-PLA2的PLA2G7基因中的某些单核苷酸多态性（SNP）具有抗动脉粥样硬化作用，但其他研究则有不同观点。因此，需要进行一项全面研究，以探讨PLA2G7基因中的SNP（V279F、A379V、R92H、I198T）对临床动脉粥样硬化的影响。
我们在PubMed、EBSCO、ProQuest、Science Direct、Springer和Cochrane数据库中检索符合条件的病例对照研究，以评估PLA2G7基因的四种SNP与临床动脉粥样硬化风险（CVD = 心血管疾病，CAD = 冠状动脉疾病，PAD = 外周动脉疾病，缺血性中风）之间的关系。所有研究均在哈迪-温伯格平衡（Hardy-Weinberg Equilibrium）下进行评估，采用加性模型。本荟萃分析由RevMan 5.3进行，以提供比值比（OR）及其95%置信区间（95%CI）的合并估计值。
14项临床研究符合我们的纳入标准。这些研究包括12432例临床动脉粥样硬化患者和10171例对照。我们发现，两种变异SNP（V279F、R92H）的OR与临床动脉粥样硬化相关{V279F，OR = 0.88（95%CI，0.81 - 0.95）；p = 0.0007，I = 40%}，{R92H，OR = 1.29（95%CI，1.09 - 1.53）；p = 0.003，I = 73%}。同时，另外两种SNP，A379V{OR = 1.08（95%CI，0.93 - 1.26）；p = 0.31，I = 78%}和I198T{OR = 1.12（95%CI = 0.79 - 1.59）；p = 0.53，I = 81%}之间无显著关联。
这些结果表明，PLA2G7基因中的V279F多态性对临床动脉粥样硬化具有保护作用，而R92H多态性可能会增加临床动脉粥样硬化的风险。
